INTERVIEW: Juno CEO Hans Bishop On The CAR-T Learning Curve
Executive Summary
Juno Therapeutics President and CEO Hans Bishop spoke with Scrip about the company's CAR-T strategy, its short-lived clinical hold and Novartis's recent cell therapy business shift.
You may also be interested in...
Novartis, Kite Neck-And-Neck In CAR-T Race; Deaths Keep Juno In Third Place
Novartis and Kite both are set to submit their CD19-targeting CAR-T therapies for US FDA approval in early 2017, while neurotoxic deaths for two of Juno’s product candidates cast doubts on its programs.
New Interim CAR-T Data Support Kite’s BLA Submission Plans
Kite Pharma Inc. executives reiterated plans on Sept. 26 to pursue US FDA approval this year for the chimeric antigen receptor T cell (CAR-T) therapy known as KTE-C19, keeping the company on track to seek accelerated approval for a form of advanced lymphoma before any of its competitors.
Novartis Cell Therapy Unit To Close: Implications For CAR-T Could Be Big
Novartis is closing its high-profile cell and gene therapy unit – the one responsible for developing CAR-T therapies. The move suggests Novartis’s outlook for the CAR-T field may be changing, though it’s not clear why.